Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

But it poses an inconvenient question: is it expanding choices for the people? ANALYSIS | SHOBHA SHUKLA | Any new HIV prevention method is not meant to sit on the shelf but to be used by the people ...

The firm says that based on progress in Gilead’s portfolio, the recent accelerated approval for Livdelzi, the potential for lenacapavir to offer 100% effective protection against HIV, and the stock’s ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Insights speaks directly to the people with an inside track on the big issues. Here, Dan Glass demands pharmaceutical company ...

Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...

Stocks struggled Thursday after Federal Reserve Chair Jerome Powell cautioned that the economy is strong enough to not rush ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...